EarningsQ2 2026 Earnings Report
MX:QUREN Q2 2026 EPS Results
Actual EPS-$22.18
Consensus EPS-$14.94
Beat/MissMissed by -$7.23
One Year Ago EPS-$12.54
MX:QUREN Q2 2026 Revenue Results
Actual Revenue$106.18M
Expected Revenue$99.05M
Beat/MissBeat by +$7.13M
YoY Revenue Growth+11.00%
Earnings Announcement Details
QuarterQ2 2026
Date07/29/2026
TimeBefore Open
Conference CallWednesday, July 29, 2026
MX:QUREN Upcoming Earnings
uniQure's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:QUREN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed strong positive momentum: regulatory progress (FDA alignment on using 3-year data as the basis for an accelerated BLA), an on-track BLA/MAA submission timeline, upcoming 4-year AMT-130 data, encouraging early efficacy and biological signals in AMT-260 and AMT-191, and a materially strengthened balance sheet with ~$810M cash supporting operations into 2030. Notable challenges include a pause in higher-dose AMT-191 dosing after Grade 3 LFTs (dose-limiting toxicity), mixed early efficacy in the AMT-260 low-dose cohort, increased SG&A to fund commercialization (near-term burn), and the operational/regulatory requirement to have the confirmatory trial well underway at the time of any accelerated approval. Taken together, the positives (regulatory clarity, data momentum, cash runway, early signals) outweigh the manageable clinical and execution risks identified.Company Guidance
Regulatory alignment for AMT-130 and near-term submission timeline
FDA Type B meeting confirmed that the 3-year Phase I/II AMT-130 data are acceptable as the primary basis for a BLA under the accelerated approval pathway; company is on track to submit the BLA in Q3 2026 and expects a parallel MHRA (U.K.) submission in Q3 2026.
Confirmatory study design allowance (no sham required)
FDA agreed that the confirmatory study does not require a sham procedure and recommended a randomized standard-of-care controlled study with total functional capacity (TFC) at 36 months as primary endpoint, reducing one potential operational barrier to study conduct.
Upcoming 4-year AMT-130 clinical readout
Company expects to conduct 4-year AMT-130 data analyses based on a June 30 cutoff and present 4-year safety/tolerability and efficacy topline results in September 2026 (includes data from 12 high- and 12 low-dose patients at 4 years, plus 3 additional high-dose patients with 3 years follow-up).
Early encouraging data for AMT-260 (epilepsy)
Phase I/II low-dose cohort (n=6) showed 3 patients with meaningful reductions in disabling seizures (79% to 100% reduction months 4-6 vs baseline); no SAEs related to AMT-260 or the surgical procedure reported and adverse events were mild/moderate; higher-dose cohort enrollment expected to complete imminently.
Promising biological activity for AMT-191 (Fabry disease)
Across 11 dosed patients (three dose levels) AMT-191 produced dose-dependent increases in alpha-Gal A activity; plasma lyso-Gb3 levels remained stable and all 11 patients remained withdrawn from enzyme replacement therapy (ERT) at reported follow-up.
Strong balance sheet and extended runway
Cash, cash equivalents and investment securities were $810.3 million as of June 30, 2026 versus $622.5 million as of December 31, 2025 (increase of $187.8 million, ~30.2%); company expects funding sufficient to support operations into 2030, including confirmatory and commercial activities.
Revenue growth quarter-over-quarter
Revenue for Q2 2026 was $5.8 million versus $5.3 million in Q2 2025, an increase of $0.5 million (~9.4%), driven by higher license revenue.
R&D spend slightly reduced year-over-year
Research & development expenses were $34.0 million in Q2 2026 versus $35.4 million in Q2 2025, a decrease of $1.4 million (~4.0%), driven by lower facility, employee/contractor costs and contingent consideration changes, partially offset by higher direct spend on AMT-260, AMT-162 and AMT-191.
MX:QUREN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed